Results 221 to 230 of about 239,193 (267)

Prognosis and Risk Stratification in Dilated Cardiomyopathy With LVEF≤35%: Cardiac MRI Insights for Better Outcomes. [PDF]

open access: yesCirc Cardiovasc Imaging
Zhou D   +17 more
europepmc   +1 more source

Communicating a diagnosis of Dravet syndrome to parents/caregivers: An international Delphi consensus

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Dravet syndrome is a developmental and epileptic encephalopathy characterized by drug‐resistance, lifelong seizures, and significant comorbidities including intellectual and motor impairment. Receiving a diagnosis of Dravet syndrome is challenging for parents/caregivers, and little research has focused on how the diagnosis should be ...
Andreas Brunklaus   +9 more
wiley   +1 more source

Self‐limited familial focal epilepsy caused by ANK2 variants: A potentially under‐recognized condition

open access: yesEpilepsia Open, EarlyView.
Abstract The Ankyrin 2 (ANK2) gene encodes the ankyrin‐B protein (ANKB), which is involved in the organization and stability of membrane ion channels, transporters, and receptors in cardiomyocytes and neurons. Variants in ANK2 genes are initially reported in long QT syndrome and autism.
Po‐Hsi Lin   +5 more
wiley   +1 more source

Heart on Fire: Unmasking <i>RyR2</i> Mutation in Stress-Induced Ventricular Arrhythmias. [PDF]

open access: yesMethodist Debakey Cardiovasc J
Sharma V   +5 more
europepmc   +1 more source

Statins' protective effects on focal epilepsy are independent of LDL‐C

open access: yesEpilepsia Open, EarlyView.
Abstract Objective This study evaluates the potential protective effects of statins against epilepsy, focusing on their differential impacts on focal and generalized epilepsy. It investigates the role of statins through the HMGCR gene and associated low‐density lipoprotein (LDL) cholesterol levels.
Zhen Sun   +6 more
wiley   +1 more source

Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐TOLE) in adults with focal epilepsy

open access: yesEpilepsia Open, EarlyView.
Abstract Objective To report interim data from an ongoing, open‐label extension (OLE) of a Phase 2b study (X‐TOLE) of azetukalner in adults with focal onset seizures (FOS) receiving 1–3 antiseizure medications. Methods Eligible participants enrolled in the 7‐year OLE at 20 mg azetukalner once daily with food.
Jacqueline A. French   +62 more
wiley   +1 more source

Sudden Cardiac Arrest Among Young Competitive Athletes Before and During the COVID-19 Pandemic.

open access: yesJAMA Netw Open
Astley C   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy